Biocure Technology Inc.
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
info@biocuretech.com
+1(604) 609-7146
© Biocure Technology Inc., all rights reserved
Biocure Technology Inc. enters into exclusive Letter Agreement to acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction
VANCOUVER, British Columbia, September 18, 2023 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE: CURE) announces that it has entered into an exclusive letter agreement dated September 8, 2023 with Atriva Therapeutics GmbH. (“Atriva”) whereby the Company will acquire all of the issued and outstanding securities of Atriva (the “Transaction”). The Transaction will be a business combination completed by way of a share exchange, share purchase, amalgamation, arrangement, takeover bid, or other similar form of transaction.
Upon the successful completion of the proposed Transaction, it is anticipated that the Company will carry on the business of Atriva (the “Resulting Issuer”). The Transaction constitutes a ‘reverse takeover’ of the Company.